EP1005346A2 - Solutions contenant des azastero des - Google Patents

Solutions contenant des azastero des

Info

Publication number
EP1005346A2
EP1005346A2 EP98941422A EP98941422A EP1005346A2 EP 1005346 A2 EP1005346 A2 EP 1005346A2 EP 98941422 A EP98941422 A EP 98941422A EP 98941422 A EP98941422 A EP 98941422A EP 1005346 A2 EP1005346 A2 EP 1005346A2
Authority
EP
European Patent Office
Prior art keywords
solution
steroid
composition
aza
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98941422A
Other languages
German (de)
English (en)
Inventor
Alan Frank Parr
Michele Catherine Rizzolio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1005346A2 publication Critical patent/EP1005346A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Definitions

  • the present invention relates to certain pharmaceutical compositions comprising 4-aza steroids and/or 6-aza steroids.
  • the present invention relates to solutions comprising a steroid 5-alpha reductase inhibitor.
  • Pharmaceutically active compounds can be delivered in a variety of forms, for example in a soft elastic gelatin capsule.
  • Methods for preparation of soft gelatin capsules are well known. See, for example, J.P. Stanley, Soft Gelatin Capsules, Ch. 13 - Part Two in: The Theory and Practice of Industrial Pharmacy, eds. L. Lachman et. al., 3 rd Ed., pp. 398-412, 1986, and W.R. Ebert, Soft Elastic Gelatin Capsules: A Unique Dosage Form, Pharmaceutical Technology, Vol. 1 , No. 5.
  • excipients are important in order to ensure good solubility and good bioavailability of the pharmaceutically active compound. See for example, A. Matso, Excipients Commonly Used in Soft Gelatin Capsules: Their Analysis and Usefulness, Novel Drug Formulation Systems and Delivery Devices International Seminar, pp. 76-81 ,(1991). K. Hutchison, Encapsulation in Softgels for Pharmaceutical Advantage, Spec. Pub. - R. Soc. Chem., Vol. 138, pp 86-97, (1993), M.S. Patel et. al., Advances in Softgel Formulation Technology, Manufacturing Chemist, August 1989, and I.R.
  • Aza steroids are an important class of pharmaceutically active compounds.
  • 4-aza steroids and 6-aza steroids known to be inhibitors of the enzyme testosterone 5-alpha-reductase (hereinafter “5AR inhibitors”).
  • 5AR inhibitors Such compounds are thought to be useful in the treatment of benign prostatic hyperplasia, prostate cancer and other diseases. See, for example, U.S. Pat. Nos.
  • finasteride is commercially available from Merck & Co., Inc. as PROSCARTM. These pharmaceutically active compounds are not easy to dissolve. These solubility challenges can affect bioavailability possibly resulting in reduced or unpredictable bioavailability.
  • the present invention discloses a novel solution comprising a therapeutically effective amount of a pharmaceutically active aza steroid, polyethylene glycol (PEG), and propylene glycol (PG).
  • a pharmaceutical composition comprising the solution of this invention.
  • the composition of this invention is particularly suitable for use as a fill formulation for gelatin capsules.
  • the present invention discloses a gelatin capsule filled with the composition of the present invention.
  • the composition of this invention has improved bioavailability over standard tablets or suspensions.
  • Some of the steroids useful in this invention are potent teratogens. Converting the steroid from a free powder to a solution early in the manufacturing process provides a safer process. There is less risk in working with the solution than with the free solid.
  • Gelatin capsule formulations can be much more resistant to oxidation due to the low oxygen permeation of typical gelatin shells. See, for example, F.S. Hom et al., Soft Gelatin capsules II: Oxygen Permeability Study of Capsule Shells, J. Pharm. Sci., Vol. 64
  • compositions of this invention have surprisingly short drying time. This surprisingly short drying time is beneficial for manufacturing because this shortens the time from manufacturing to packaging and shipping, thereby lowering manufacturing cost.
  • the aza steroids useful in this invention can be any pharmaceutically active aza steroid or pharmaceutically acceptable solvate thereof.
  • Preferred classes of aza steroids are the 4-azasteroid class of 5-alpha reductase inhibitors (5AR inhibitors) and the 6-aza class of 5-alpha reductase inhibitors.
  • 5AR inhibitors any of the 5AR inhibitors disclosed in the above cited patents.
  • Particularly preferred aza steroids are the 4-aza steroids.
  • Particularly preferred 4-aza steroids include finasteride, 17- beta-N-(2,5,-bis(trifluoromethyl))phenylcarbamoyl-4-aza-5-alpha-androst-1-en-3-one which is the steroid is that disclosed in U.S. Pat. No.
  • 5-alpha-androst-1-en-3-one which are both disclosed in WO 95/07926 (Batchelor et al.).
  • These steroids can be prepared by well-known methods, for example as described in the above cited patents.
  • the aza steroid is preferably present in the range of from 0.00075 to 0.4% by weight of the solution of this invention, more preferably from 0.0075 to 0.3 % by weight of the solution of this invention.
  • the PEG useful in this invention preferably has an average molecular weight range of 200-600, at which PEG is in liquid state. Particularly preferred is PEG with an average molecular weight of around 400 (PEG 400).
  • PEG 400 PEG with an average molecular weight of around 400
  • PEG is at least 90% by weight of the solution of this invention.
  • the PG is preferably from 1 to 7.5% by weight of the solution of this invention, more preferably from 4 to 6% by weight of the solution.
  • a surfactant include, polyoxyethylene(20)sorbitan monooleate (Polysorbate 80), sodium dodecyl sulfate, and dioctylsulfosuccinate sodium salt (Docusate sodium).
  • Surfactants may be used alone or in combination.
  • a particularly preferred surfactant is Polysorbate 80.
  • the surfactant or surfactant mixture is preferably from 0.05 to 1.0% by weight of the composition of this invention.
  • Suitable anti-oxidants include butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and ascorbic acid.
  • BHT butylated hydroxytoluene
  • BHA butylated hydroxyanisole
  • ascorbic acid A particularly preferred anti-oxidant is butylated hydroxytoluene.
  • Antioxidants may be used alone or in combination.
  • the antioxidant or mixture of antioxidants is preferably from 0.001 to 0.5% by weight of the composition of this invention.
  • the pharmaceutical composition of the present invention is particularly useful as a fill formulation for gelatin capsules, most preferably soft gelatin capsules.
  • a pharmaceutically active 4-aza steroid was utilized in various solubility studies.
  • the pharmaceutically active steroid utilized was 17-beta-N-(2,5,-bis(trifluoromethyl))phenylcarbamoyl-4-aza-5-alpha-androst-1 -ene-3- one.
  • This steroid is described in the '467 patent and can be prepared by known methods including the methods described in the '467 patent.
  • the solubility of the steroid was determined by suspending excess amount of the steroid in about 1 ml_ of various aqueous and organic media. The resulting suspension was tumbled in a Vankel® rotating water bath maintained at 25°C and protected from light. At the end of an equilibration time, usually between 1 and 12 days, excess solid was removed by filtercentrifugation through 0.22 ⁇ filters. The resulting supernatant was then assayed for steroid concentration against an external standard. The concentration of steroid in the supernatant was determined by HPLC analyses using a Hewlett Packard 1090 Series ll/M with a DOS Chem Station. The HPLC conditions are summarized below in Table 1.
  • Table 2 The results of the solubility in various aqueous media is summarized in Table 2, and in various organic media is summarized in Table 3.
  • Table 4 summarizes the solubility in various compositions containing a complexing agent (2-hydroxypropyl-beta-cyclodextrin).
  • Table 5 summarizes the solubility in various oils.
  • Mili QTM plus water is a reverse osmosis water
  • THF is tetrahydrofuran
  • DMSO dimthylsulfoxide
  • LabrafilTM is a mixture of unsaturated polyglycolyzed gylcerides obtained by partial alcoholysis of corn oil or apricot kernel oil, consisting of glycerides and polyethylene glycol esters
  • SDS is sodium dodecyl sulfate
  • "model duodenum bile salts” is a mixture of sodium glycocholate, sodium glycochenodesoxycholate, sodium glycodesoxycholate, sodium taurocholate, sodium taurochenodesoxycholate, sodium taurodesoxycholate, sodium chloride, lecithin
  • Tween 80 is polyoxyethylene(20)sorbitan monooleate
  • the PEG 400 was purchased from Union Carbide
  • MolescusolTM is 2- hydroxypropyl-beta-cyclodextrin
  • compositions suitable for use in gelatin capsules were then used to prepare fill formulations suitable for use in gelatin capsules.
  • propylene glycol USP was heated to 35-50°C.
  • butylated Hydroxytoluene NF is added and the mixture is stirred until dissolved.
  • Polysorbate 80 NF was then added and mixed.
  • the steroid was added and mixed, heating to 40-45°C if necessary, until dissolved.
  • the solution was deaerated prior to encapsulation.
  • the gelatin was prepared by blending gelatin NF, glycerin USP, and purified water USP. The resulting mixture was heated in a pressurized reactor to melt the gelatin. The gelatin was then maintained in the molten state until used for encapsulation. Encapsulation was performed using a rotary die process. The heated gelatin was fed to an encapsulation machine where it entered two spreader boxes which cast the gelatin on a cooling drum, thus forming two gelatin ribbons. Each gelatin ribbon was lubricated with Fractionated Coconut Oil on the internal side and Fractionated Coconut Oil with 0.1% Lecithin NF on the external side.
  • the Fractionated Coconut Oil prevents the gelatin from sticking to equipment and the Lecithin NF prevents the capsules from sticking together after manufacture, prior to drying.
  • the ribbons were then conveyed to the encapsulation roller. Die cavities to form the capsules are located on the circumference of the two adjacent rollers, which rotate and pull the gelatin ribbons between them.
  • the fill solution was injected, by a metered positive-displacement pump, between the gelatin ribbons forcing them to expand and fill the die cavities.
  • the capsules were then conveyed to the rotating basket dryer.
  • the capsules were dried by tumbling in a rotating basket dryer to remove sufficient moisture to allow handling.
  • the batches were then evaluated for drying times.
  • the drying time for all of the PEG based compositions that were tested was only 1 day.
  • soft gelatin capsules containing oil based (hydrophobic) fill material to have drying times of about 3 days, and that PEG based fill materials typically increase drying time compared to oil based compositions. Therefore, the shorter drying time of the PEG based formulation of steroid offers an advantage over typical PEG based formulations, as well as typical oil based formulations.
  • propylene glycol typically decreases water migration into the fill, propylene glycol typically has no significant effect on drying time. In our case however, propylene glycol results in a greater than expected decrease in drying time.
  • compositions were also evaluated for relative bioavailability using standard methods. Volunteers were randomized to receive drug in either an oral solution of the present invention, a soft gelatin capsule of the present invention, or in a standard tablet. Plasma samples were collected and pharmaco kinetic parameters (AUC, C max , T max ) were compared between the treatment groups. The relative bioavailability from the solution and soft gelatin capsule of the present invention was 80% to 90% compared to 10% to 20% for the same amount of steroid in a tablet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle solution renfermant une quantité thérapeutiquement efficace d'un stéroïde aza pharmaceutiquement actif, un polyéthylène glycol et un propylène glycol. Dans un deuxième aspect, cette invention concerne une composition pharmaceutique renfermant la solution de l'invention. Enfin, dans un troisième aspect, cette invention concerne une capsule de gélatine remplie avec la composition de l'invention.
EP98941422A 1997-08-19 1998-08-17 Solutions contenant des azastero des Withdrawn EP1005346A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9717444 1997-08-19
GBGB9717444.5A GB9717444D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition
PCT/EP1998/005192 WO1999008684A2 (fr) 1997-08-19 1998-08-17 Solutions contenant des azasteroïdes

Publications (1)

Publication Number Publication Date
EP1005346A2 true EP1005346A2 (fr) 2000-06-07

Family

ID=10817633

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98941422A Withdrawn EP1005346A2 (fr) 1997-08-19 1998-08-17 Solutions contenant des azastero des

Country Status (10)

Country Link
EP (1) EP1005346A2 (fr)
JP (1) JP2002511100A (fr)
KR (1) KR20010014079A (fr)
CN (1) CN1263466A (fr)
AU (1) AU8979698A (fr)
BR (1) BR9810285A (fr)
CA (1) CA2295023A1 (fr)
GB (1) GB9717444D0 (fr)
TR (1) TR199903211T2 (fr)
WO (1) WO1999008684A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
WO2005066195A1 (fr) * 2004-01-02 2005-07-21 Pharmacon Forschung Und Beratung Gmbh Procede de production d'azasteroides insatures en position 1,2
EP2050436A1 (fr) 2007-12-21 2009-04-22 Siegfried Generics International AG Composition pharmaceutique qui comporte de la dutastéride
DE102008059201A1 (de) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
KR101055412B1 (ko) * 2010-11-19 2011-08-08 (주)비씨월드제약 두타스테라이드를 포함하는 자가유화 에멀젼 조성물 및 이의 제조방법
CN103169712B (zh) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 提高生物利用度的度他雄胺制剂及其制备方法
SG10201609364QA (en) * 2012-05-18 2017-01-27 Luoda Pharma Pty Ltd Liquid formulation
CN103479595B (zh) * 2012-06-13 2015-08-26 成都国弘医药有限公司 一种含有度他雄胺的软胶囊
WO2014002015A1 (fr) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant du dutastéride
CN103830201A (zh) * 2012-11-20 2014-06-04 重庆医药工业研究院有限责任公司 一种度他雄胺液体软胶囊
EP2949319A1 (fr) 2014-05-26 2015-12-02 Galenicum Health S.L. Compositions pharmaceutiques comprenant un agent actif
JP7017938B2 (ja) * 2018-01-15 2022-02-09 森下仁丹株式会社 ３－オキソ－４－アザアンドロスト－１－エン－１７－カルボン酸誘導体含有製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516768A (en) * 1990-03-16 1996-05-14 Smithkline Beecham Corporation Uncompetitive inhibition of steroid and 5α-reductose
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
AU7078296A (en) * 1995-09-27 1997-04-17 Merck & Co., Inc. Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors
WO1998025463A1 (fr) * 1996-12-09 1998-06-18 Merck & Co., Inc. Procedes et compositions permettant de prevenir et de traiter la perte osseuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9908684A2 *

Also Published As

Publication number Publication date
CN1263466A (zh) 2000-08-16
GB9717444D0 (en) 1997-10-22
WO1999008684A3 (fr) 1999-06-10
WO1999008684A2 (fr) 1999-02-25
AU8979698A (en) 1999-03-08
CA2295023A1 (fr) 1999-02-25
JP2002511100A (ja) 2002-04-09
BR9810285A (pt) 2000-09-12
TR199903211T2 (xx) 2000-04-21
KR20010014079A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
TWI490216B (zh) 用作ｃ型肝炎病毒蛋白酶抑制劑之醫藥組合物
KR100425755B1 (ko) 이트라코나졸을 함유하는 조성물 및 그 제조방법
EP1005346A2 (fr) Solutions contenant des azastero des
WO2004054540A3 (fr) Formulations solides a ecoulement facile presentant une biodisponibilite amelioree de medicaments faiblement solubles dans l'eau et leur procede de fabrication
WO2009069139A1 (fr) Forme posologique fournissant un remplissage liquide contenant de l'ibuprofène
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
AU768796B2 (en) Capsule system
DK2575784T3 (en) ORAL DOSAGE FORMS OF BENDAMUSTIN
EP1007010A2 (fr) Composition pharmaceutique
EP3854384A1 (fr) Formulation pharmaceutique comprenant de l'acétate d'abiratérone
MXPA99011995A (en) Solutions containing azasteroids
MXPA99011970A (en) Pharmaceutical composition
CA3050347C (fr) Capsules molles contenant de l'hydroxypropyl-beta-cyclodextrine d'une grande stabilite
KR20020039354A (ko) 바소프레신 길항제 제형 및 방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991222

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991222;LT PAYMENT 19991222;LV PAYMENT 19991222;MK PAYMENT 19991222;RO PAYMENT 19991222;SI PAYMENT 19991222

17Q First examination report despatched

Effective date: 20020221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020301

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1028349

Country of ref document: HK